[1]
|
H. Rauschecker, M. Clarke, W. Gatzemeier and A. Recht, “Systemic Therapy for Treating Locoregional Recurrence in Women with Breast Cancer,” Cochrane Database of Systematic Reviews, 2001, CD002195.
|
[2]
|
F. Aydogan, V. Ozben, D. Atasoy, M. H. Yilmaz, M. Hala? and V. Celik, “Excision of Axillary Lymph Node Recurrences in Breast Cancer Patients with Axillary ROLL (A-ROLL),” Journal of Surgical Oncology, Vol. 101, No. 2, 2010, pp. 141-144.
|
[3]
|
H. J. Kim, J. Y. Kwak, J. W. Choi, et al., “Impact of US Surveillance on Detection of Clinically Occult Locoregional Recurrence after Mastectomy for Breast Cancer,” Annals of Surgical Oncology, Vol. 17, No. 10, 2010, pp. 2670-2676. http://dx.doi.org/10.1245/s10434-010-1087-z
|
[4]
|
S. Aebi, T. Davidson, G. Gruber, F. Cardoso and ESMO Guidelines Working Group, “Primary Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up,” Annals of Oncology, Vol. 22, Suppl. 6, 2011, pp. S12-S24.
http://dx.doi.org/10.1093/annonc/mdr371
|
[5]
|
H. Torrenga, H. Fabry, J. R. van der Sijp, P. J. van Diest, R. Pijpers and S. Meijer, “Omitting Axillary Lymph Node Dissection in Sentinel Node Negative Breast Cancer Patients Is Safe: A Long Term Follow-Up Analysis,” Journal of Surgical Oncology, Vol. 88, No. 1, 2004, pp. 4-7.
http://dx.doi.org/10.1002/jso.20101
|
[6]
|
L. Sobin, M. Gospodarowicz and C. Wittekind, Eds., “UICC TNM Classification of Malignant Tumors,” 7th Edition, John Wiley & Sons, Inc., Hoboken, 2009.
|
[7]
|
N. M. Perry and EUSOMA Working Party, “Quality Assurance in the Diagnosis of Breast Disease. EUSOMA Working Party,” European Journal of Cancer, Vol. 37, No. 2, 2001, pp. 159-172.
http://dx.doi.org/10.1016/S0959-8049(00)00337-3
|
[8]
|
H. Ojeda-Fournier and J. Q. Nguyen, “Ultrasound Evaluation of Regional Breast Lymph Node,” Seminars in Roentgenology, Vol. 46, No. 1, 2011, pp. 51-59.
http://dx.doi.org/10.1053/j.ro.2010. 06.007
|
[9]
|
F. Sakai, K. Kiyono, S. Sone, et al., “Ultrasonic Evaluation of Cervical Metastatic Lymphadenopathy,” Journal of Ultrasound in Medicine, Vol. 7, No. 6, 1988, pp. 305-310.
|
[10]
|
A. Luparia, P. Campanino, R. Cotti, et al., “Role of Axillary Ultrasound in the Preoperative Diagnosis of Lymph Node Metastases in Patients Affected by Breast Carcinoma,” Radiologia Medica, Vol. 115, No. 2, 2010, pp. 225-237. http://dx.doi.org/10.1007/s11547-009-0465-8
|
[11]
|
J. Nori, E. Vanzi, M. Bazzocchi, et al., “Role of Axillary Ultrasound Examination in the Selection of Breast Cancer Patients for Sentinel Node Biopsy,” American Journal of Surgery, Vol. 193, No. 6, 2007, pp. 16-20.
http://dx.doi.org/10.1016/j.amjsurg.2006.02.021
|
[12]
|
S. Alvarez, E. Anorbe, P. Alcorta, et al., “Role of Sonography in the Diagnosis of Axillary Lymph Node Metastases in Breast Cancer: A Systematic Review,” American Journal of Roentgenology, Vol. 186, No. 5, 2006, pp. 1342-1348. http://dx.doi.org/10.2214/AJR.05.0936
|
[13]
|
J. H. Shin, B. K. Han, Y. H. Choe, et al., “Ultrasonographic Detection of Occult Cancer in Patients after Surgical Therapy for Breast Cancer,” Journal of Ultrasound in Medicine, Vol. 24, No. 5, 2005, pp. 643-649.
|
[14]
|
T. Susini, J. Nori, E. Vanzi, et al., “Axillary Ultrasound Scanning in the Follow-Up of Breast Cancer Patients Undergoing Sentinel Node Biopsy,” Breast, Vol. 16, No. 2, 2007, pp. 190-196.
http://dx.doi.org/10.1016/j.breast.2006.10.004
|
[15]
|
H. J. Moon, M. J. Kim, E. K. Kim, et al., “US Surveillance of Regional Lymph Node Recurrence after Breast Cancer Surgery,” Radiology, Vol. 252, No. 3, 2009, pp. 673-681. http://dx.doi.org/10. 1148/radiol.2523081977
|
[16]
|
J. H. Lee, E. K. Kim, J. Y. Oh, et al., “US Screening for Detection of Nonpalpable Locoregional Recurrence after Mastectomy,” European Journal of Radiology, Vol. 82, No. 3, 2013, pp. 485-489.
http://dx.doi.org/10.1016/j.ejrad.2012.10.007
|
[17]
|
H. Abe, R. A. Schmidt, K. Kulkarni, C. A. Sennett, J. S. Mueller and G. M. Newstead, “Axillary Lymph Nodes Suspicious for Breast Cancer Metastasis: Sampling with US-Guided 14-Gauge Core-Needle Biopsy—Clinical Experience in 100 Patients,” Radiology, Vol. 250, No. 1, 2009, pp. 41-49.
http://dx.doi.org/10.1148/radiol.2493071483
|
[18]
|
H. Abe, R. A. Schmidt, C. A. Sennett, A. Shimauchi and G. M. Newstead, “US-Guided Core Needle Biopsy of Axillary Lymph Nodes in Patients with Breast Cancer: Why and How to Do It,” Radiographics, Vol. 27, Suppl. 1, 2007, pp. S91-S99.
http://dx.doi.org/10.1148/rg.27si075502
|
[19]
|
S. L. Koelliker, M. A. Chung, M. Mainiero, et al., “Axillary Lymph Nodes: US-Guided Fine-Needle Aspiration for Initial Staging of Breast Cancer—Correlation with Primary Tumor Size,” Radiology, Vol. 246, No. 1, 2008, pp. 81-89. http://dx.doi.org/10.1148/radiol.2463061463
|
[20]
|
S. Wojcinski, A. Farrokh, U. Hille, et al., “Optimizing Breast Cancer Follow-Up: Diagnostic Value and Costs of Additional Routine Breast Ultrasound,” Ultrasound in Medicine and Biology, Vol. 37, No. 2, 2011, pp. 198-206.
http://dx.doi.org/10.1016/j.ultrasmedbio.2010.10.024
|
[21]
|
U. Veronesi, R. Orecchia, S. Zurrida, et al., “Avoiding Axillary Dissection in Breast Cancer Surgery: A Randomized Trial to Assess the Role of Axillary Radiotherapy,” Annals of Oncology, Vol. 16, No. 3, 2005, pp. 383-388.
http://dx.doi.org/10.1093/annonc/mdi089
|
[22]
|
I. M. Van der Ploeg, B. B. Kroon, N. Antonini, et al., “Axillary and Extra-Axillary Lymph Node Recurrences after a Tumor-Negative Sentinel Node Biopsy for Breast Cancer Using Intralesional Tracer Administration,” Annals of Surgical Oncology, Vol. 15, No. 4, 2008, pp. 1025-1031. http://dx.doi.org/10.1245/s10434-007-9760-6
|
[23]
|
A. E. Giuliano, L. McCall, P. Beitsch, et al., “Locoregional Recurrence after Sentinel Lymph Node Dissection with or without Axillary Dissection in Patients with Sentinel Lymph Node Metastases: The American College of Surgeons Oncology Group Z0011 Randomized Trial,” Annals of Surgery, Vol. 252, No. 3, 2010, pp. 426-432.
|
[24]
|
I. M. Van der Ploeg, O. E. Nieweg, M. C. van Rijk, et al., “Axillary Recurrence after a Tumour-Negative Sentinel Node Biopsy in Breast Cancer Patients: A Systematic Review and Meta-Analysis of the Literature,” European Journal of Surgical Oncology, Vol. 34, No. 12, 2008, pp. 1277-1284. http://dx.doi.org/10.1016/j.ejso.2008.01.034
|
[25]
|
H. Takei, K. Suemasu, M. Kurosumi, et al., “Recurrence after Sentinel Lymph Node Biopsy with or without Axillary Lymph Node Dissection in Patients with Breast Cancer,” Breast Cancer, Vol. 14, No. 1, 2007, pp. 16-24.
http://dx.doi.org/10.2325/jbcs.14.16
|
[26]
|
U. Veronesi, V. Galimberti, G. Paganelli, et al., “Axillary Metastases in Breast Cancer Patients with Negative Sentinel Nodes: A Follow-Up of 3548 Cases,” European Journal of Cancer, Vol. 45, No. 8, 2009, pp. 1381-1388.
http://dx.doi.org/10.1016/j.ejca.2008.11.041
|
[27]
|
S. Bernardi, S. Bertozzi, A. P. Londero, et al., “Nine Years of Experience with the Sentinel Lymph Node Biopsy in a Single Italian Center: A Retrospective Analysis of 1050 Cases,” World Journal of Surgery, Vol. 36, No. 4, 2012, pp. 714-722.
http://dx.doi.org/10.1007/s00268-011-1420-0
|
[28]
|
A. E. Giuliano, K. K. Hunt, K. V. Ballman, et al., “Axillary Dissection vs No Axillary Dissection in Women with Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial,” JAMA, Vol. 305, No. 6, 2011, pp. 569-575.
http://dx.doi.org/10.1001/jama.2011.90
|
[29]
|
V. Galimberti, E. Botteri, C. Chifu, et al., “Can We Avoid Axillary Dissection in the Micrometastatic Sentinel Node in Breast Cancer?” Breast Cancer Research and Treatment, Vol. 131, No. 3, 2012, pp. 819-825.
http://dx.doi.org/10.1007/s10549-011-1486-2
|
[30]
|
V. Galimberti, B. F. Cole, S. Zurrida, et al., “Axillary Dissection versus No Axillary Dissection in Patients with Sentinel-Node Micrometastases (IBCSG 23-01): A Phase 3 Randomised Controlled Trial,” Lancet Oncology, Vol. 14, No. 4, 2013, pp. 297-305.
http://dx.doi.org/10.1016/S1470-2045(13)70035-4
|